[Testosterone substitution therapy in prostate cancer].

Area of Science:

• Andrology
• Urology
• Endocrinology

Background:

• Testosterone levels decline with age, potentially causing late-onset hypogonadism (LOH) or partial androgen deficiency in aging males (PADAM).
• LOH symptoms include decreased libido and erectile dysfunction, often necessitating testosterone substitution therapy (TST).

Purpose of the Study:

• To evaluate the safety and efficacy of TST in men with a history of successfully treated prostate cancer.
• To provide guidance on managing TST in patients with a history of localized prostate cancer.

Main Methods:

• Review of existing data on testosterone substitution therapy in men with prior curative treatment for prostate cancer.
• Analysis of patient outcomes regarding prostate cancer relapse and LOH symptom improvement.

Main Results:

• Limited data suggest TST is possible without increased relapse risk in patients with previously cured prostate cancer, irrespective of treatment modality (surgery or radiation).
• Regular surveillance and patient education are crucial for safe TST administration.

Conclusions:

• TST can be considered for men with a history of cured prostate cancer, provided regular monitoring is in place.
• For active or untreated prostate cancer, TST decisions require individualized risk-benefit assessment regarding disease progression.